ANI Pharmaceuticals
ANIP
$65.36
Share price
0.63%
Change (1 day)
75.27%
Change (1 year)
Categories
P/S ratio for ANI Pharmaceuticals (ANIP)
P/S ratio as of April 2024 (TTM): 2.82
According to ANI Pharmaceuticals's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.81639. At the end of 2023 the company had a P/S ratio of 2.31.
P/S ratio history for ANI Pharmaceuticals from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 2.31 | 4.25% |
| 2022 | 2.22 | -37.55% |
| 2021 | 3.55 | 106.33% |
| 2020 | 1.72 | -52.33% |
| 2019 | 3.61 | 36.37% |
| 2018 | 2.65 | -37.62% |
| 2017 | 4.25 | -22.25% |
| 2016 | 5.46 | -19.72% |
| 2015 | 6.80 | -40.75% |
| 2014 | 11.5 | 46.48% |
| 2013 | 7.84 | -40.11% |
| 2012 | 13.1 | -89.69% |
| 2011 | 127 | 134.16% |
| 2010 | 54.2 | -12.34% |
| 2009 | 61.8 | 748.33% |
| 2008 | 7.29 | -96.5% |
| 2007 | 208 | 4549.39% |
| 2006 | 4.48 | -98.36% |
| 2005 | 274 | -79.87% |
| 2004 | > 1000 | 4366.23% |
| 2003 | 30.5 | 383.09% |
| 2002 | 6.31 | -78.89% |
| 2001 | 29.9 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 3.90 | 38.39% | 🇨🇭 Switzerland |
 Pfizer PFE | 2.46 | -12.73% | 🇺🇸 USA |
 Cardinal Health CAH | 0.1162 | -95.87% | 🇺🇸 USA |
 Jazz Pharmaceuticals JAZZ | 1.78 | -36.81% | 🇮🇪 Ireland |
 Evoke Pharma
EVOK | 0.7495 | -73.39% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | 346 | 12,202.49% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | 0.9871 | -64.95% | 🇮🇱 Israel |
 Royalty Pharma RPRX | 7.10 | 152.26% | 🇬🇧 UK |
 Lannett Company LCI | 0.0238 | -99.16% | 🇺🇸 USA |